Study: Improvement in glycemic parameters by adding dapagliflozin to metformin in T2D

Study: Improvement in glycemic parameters by adding dapagliflozin to metformin in T2D
Credit: Mary Ann Liebert, Inc., publishers

Researchers used continuous glucose monitoring (CGM) to assess the effects of adding dapagliflozin to a regimen of either metformin or insulin in patients with type 2 diabetes (T2D) and found significant reductions in mean glucose and other glycemic factors, with greater improvements seen in patients taking metformin compared to insulin. The design and results of this trial are published in Diabetes Technology & Therapeutics (DTT).

CGM was used to determine daily variations in glucose during the week before received dapagliflozin and during the last week of treatment. Dapagliflozin is a U.S. FDA-approved inhibitor of sodium-glucose cotransporter 2 (SGLT2) and by blocking SGLT2 it increases urinary glucose excretion and improves glucose control. CGM was able to show the effects of adding dapagliflozin to either metformin or insulin in terms of overall mean glucose concentration, fasting , postprandial glucose, time spent in the target glucose range, and glucose variability.

The article entitled "Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial," was coauthored by Robert Henry, MD, University of California San Diego School of Medicine and colleagues from UC San Diego School of Medicine, Integrated Medical Development (Princeton Junction, NJ), Medpace (Cincinnati, OH), and AstraZeneca (Fort Washington, PA).

"["As we move beyond A1c to measure glucose control, the use of CGM is becoming more important especially in insulin-requiring patients with diabetes. Time in range (TIR) and other metrics to measure glucose variability may closely relate with a patient's overall control," says DTT Editor-in-Chief Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver (Aurora). "Henry and colleagues emphasize the importance of adding an SGLT2 inhibitor on different metrics of as measured by CGM."


Explore further

WHO issues recommendations for Tx intensification in T2DM

More information: Robert R. Henry et al, Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial, Diabetes Technology & Therapeutics (2018). DOI: 10.1089/dia.2018.0052
Citation: Study: Improvement in glycemic parameters by adding dapagliflozin to metformin in T2D (2018, October 1) retrieved 18 June 2019 from https://medicalxpress.com/news/2018-10-glycemic-parameters-adding-dapagliflozin-metformin.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Oct 02, 2018
Cinnamon reduces blood sugar spikes Marijuana causes the body to produce more insulin by acting on receptors. Research has progressed further than what is reported in google on Marijuana and diabetes

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more